On April 27, 2022 Alligator Bioscience AB reported that Interim report January–March 2022 (Press release, Alligator Bioscience, APR 27, 2022, View Source [SID1234613014])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIGNIFICANT EVENTS JANUARY-MARCH

Pipeline:

In March, the Company successfully completed the Phase Ib part of the clinical study OPTIMIZE-1, and Phase II is now enrolling patients at the recommended dose of 900 µg/kg.
In January, Alligator initiated a sponsored research collaboration with Dr. Beatty of University of Pennsylvania to support OPTIMIZE-1, and at the same time we welcomed Dr. Beatty as advisor to Alligator.
Company:

Sumeet Ambarkhane was appointed as new Chief Medical Officer to strengthen Alligator’s efforts to further advance the development of our novel immuno-oncology pipeline in the coming year.
The Nomination Committee proposed that the Annual General Meeting 2022 re-elects the current board members, and that Staffan Encrantz and Denise Goode are elected as new board members.
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

On April 1, Alligator announced the completion of the 600 mg dose cohort for ATOR-1017, where data indicates no significant safety concerns, with stable disease as the best tumor response. Patient enrollment and treatment for the highest planned dose cohort, 900 mg, has commenced.
FINANCIAL SUMMARY

January–March 2022

Net sales, SEK 5.4 million (0.6)
Operating profit/loss, SEK -43.0 million (-32.5)
Profit/loss for the period, SEK -43.1 million (-32.7)
Earnings per share before and after dilution, SEK -0.20 (-0.42)*
Cash flow for the period, SEK -43.8 million (40.4)
Cash and cash equivalents, SEK 234.4 million (278.1)
*) Previous periods have been adjusted, see Note 8, page 20 in the attached report.

The full report is attached as PDF available on the company’s website: View Source

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on April 27, 2022.